Scilex, a Sorrento Company, Announces Pivotal Phase 3
SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...
Stay updated with breaking news from Text View. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...
PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of...
Priority Review granted by US-FDA March 28, 2022
/PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and...
Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140...